Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 64 citations in OpenAlex.

1. Frequency of Founder Mutations inCancers · 2026
   Review
2. Medullary breast cancer and germline BRCA1 mutations: a possible criterion for genetic testing.Hereditary cancer in clinical practice · 2025
   Review
3. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.Human mutation · 2018
   Article
4. Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.Familial cancer · 2013
   Article
5. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer.BioMed research international · 2013
   Review
6. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.The EPMA journal · 2010
   Article
7. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection.Journal of experimental & clinical cancer research : CR · 2010
   Article
8. Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing.World journal of gastroenterology · 2007
   Article
9. Molecular and genealogical characterization of the R1443X BRCA1 mutation in high-risk French-Canadian breast/ovarian cancer families.Human genetics · 2005
   Article
10. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area.Breast cancer research : BCR · 2005
    Article
11. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.Familial cancer · 2005
    Article
12. Founder mutations in the BRCA1 gene in Polish families with breast-ovarian cancer.American journal of human genetics · 2000
    Article
13. Evidence of a founder BRCA1 mutation in Scotland.British journal of cancer · 2000
    Article
14. Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.British journal of cancer · 2000
    Article
15. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes.American journal of human genetics · 1999
    Article
16. Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families.American journal of human genetics · 1998
    Article
17. The genetics of inherited breast cancer.Journal of mammary gland biology and neoplasia · 1998
    Review
18. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia.American journal of human genetics · 1997
    Article
19. Population genetics of BRCA1 and BRCA2.American journal of human genetics · 1997
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

8 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as